Several drugs directly target BCL2, among which venetoclax is the most promising, showing anti-tumor activity in a xenograft model of DLBCL and impressive response in patients with chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML) [7–9]. This evidence concerns the gene BCL2 and diffuse large B-cell lymphoma.